Drug

Everolimus (Afinitor)

An mTOR inhibitor tablet for breast cancer, kidney cancer and neuroendocrine tumours

Updated: 27 October 20261 min read2 references
Generic name
Everolimus
Brand names
Afinitor
Drug class
mTOR inhibitor
Route
Oral (tablet)
Show content for:

Key points

  • Everolimus is one 10 mg tablet a day [1].
  • With exemestane, it kept advanced hormone receptor-positive breast cancer under control for longer [2].
  • Mouth sores are the most common side effect; a dexamethasone mouthwash from day one helps.

What is this drug and how does it work?

For patients

Everolimus blocks a growth pathway in cancer cells (mTOR) and also reduces the growth of tumour blood vessels [1].

For physiciansSpecialist notes
For physicians

An mTORC1 inhibitor (binds FKBP-12) [1].

Which cancers is it used for?

For patients
What is this drug for?
  • Advanced hormone receptor-positive, HER2-negative breast cancer, with exemestane [1, 2]
  • Advanced kidney cancer after previous treatment [1]
  • Neuroendocrine tumours of the pancreas, lung and gut [1]
For physiciansApproved uses and evidence
For physicians
Approved uses and evidence
DiseaseUseKey evidence
Advanced HR+‎ breast cancer after a non-steroidal aromatase inhibitorWith exemestaneBOLERO-2: median progression-free survival 6.9 vs 2.8 months (local assessment) [2]
Kidney cancer, neuroendocrine tumours[1]—

How it is taken and dosing

Show detailsHide

Take it once a day at the same time, either always with food or always without, swallowed whole with water [1]. Do not eat grapefruit.

For physiciansStandard dosing (FDA label), 1 regimen
For physicians

Standard dosing (FDA label)

Everolimus

Breast, kidney and neuroendocrine cancersCycle length: Daily

Breast, kidney and neuroendocrine cancers

DrugDoseRouteSchedule
Everolimus10 mg once dailyOralDaily
Cycle length
Daily
Duration
Until progression or toxicity

Grade 2 stomatitis: hold until grade 0 or 1 and resume at the same dose; on recurrence: 50% of the dose; grade 3: hold and resume at 50%; grade 4: discontinue. Lower dose in hepatic impairment; avoid strong CYP3A4 inhibitors [1].

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Side effects

For patients

The most common side effects: mouth sores, infections, rash, tiredness, diarrhoea, swelling, nausea, poor appetite and raised blood sugar and blood fats [1].

For physiciansSpecialist notes
For physicians

Stomatitis, infections, rash, fatigue, diarrhoea, oedema, nausea, anorexia; hyperglycaemia, hypercholesterolaemia, anaemia [1].

Serious side effects

For patients

Serious side effects: lung inflammation without infection (pneumonitis), serious infections, kidney damage, slow wound healing and a big rise in blood sugar [1].

For physiciansSpecialist notes
For physicians
  • Non-infectious pneumonitis: assess with respiratory symptoms; grade 2: hold and give steroids [1].
  • Infections, renal failure, impaired wound healing, hyperglycaemia and dyslipidaemia [1].
  • Live vaccines are contraindicated [1].

When should I call my doctor?

  • A new cough or shortness of breath
  • Fever
  • Painful mouth sores that stop you eating
  • Great thirst and passing a lot of urine

Interactions, pregnancy and precautions

  • Mouth sores: an alcohol-free mouthwash and, if your doctor advises, a dexamethasone mouthwash from day one.
  • Other medicines: antifungal drugs, clarithromycin and grapefruit raise the drug level; rifampicin and epilepsy medicines lower it [1].
  • Pregnancy: this drug may harm an unborn baby; use effective contraception during treatment and tell your doctor straight away if you become pregnant. Do not breastfeed during treatment [1].
For patients

Frequently asked questions

Why do I get mouth sores?

Mouth sores are the most common side effect of everolimus and usually appear in the first weeks; tell your doctor early so treatment or the dose can be adjusted [1].

Related cancer types

References

2 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    AFINITOR (EVEROLIMUS) — Prescribing InformationNovartis Pharmaceuticals Corporation · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
  2. 2
    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerBaselga J, Campone M, Piccart M, et al · N Engl J Med · 2012;366:520-9
    Study cardDOIPubMed Back to text: 1 2 3

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.